Discover how melanoma vaccines are gaining traction in the clinic and could soon become a treatment option for this deadly skin cancer.| Labiotech.eu
On its way to tackle cancer therapy resistance with its monoclonal antibody visugromab, CataLym completes a $150 million series D round.| Labiotech.eu